Vanda Pharmaceuticals Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Vanda Pharmaceuticals Inc. on June 5, 2007. The report addresses corporate governance changes, specifically the departure of a director and the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Director Resignation: James B. Tananbaum, M.D., Ph.D., resigned from the Board of Directors effective June 5, 2007.
- Director Appointment: Howard Pien, age 49, was appointed as a Class I Director to fill the vacancy, with a term expiring at the 2010 annual meeting.
- Compensation Grant: Mr. Pien was granted an option to purchase 35,000 shares of common stock at an exercise price of $21.39 per share. The option vests in equal monthly installments over four years, with acceleration upon a change of control.
- Committee Assignment: Mr. Pien was assigned to the Compensation Committee, replacing Dr. Tananbaum.
- Indemnification: An indemnification agreement was executed with Mr. Pien, consistent with agreements for other directors and executive officers.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, outlook, management commentary on operations, or specific risk factors. The Board has determined that Mr. Pien qualifies as an independent director under SEC and NASDAQ rules.
Key Facts for Investor Verification
- Verify the independence status of the newly appointed director, Howard Pien.
- Confirm the vesting schedule and exercise price ($21.39) of the 35,000 share option granted to Mr. Pien.
- Review the impact of the Compensation Committee leadership change on future executive compensation policies.
- Check for any subsequent filings regarding the reasons for Dr. Tananbaum's resignation.